What is the catalog number for Pefloxacin-d5?

The catalog number for Pefloxacin-d5 is HY-B0147S.

What sizes are available for Pefloxacin-d5?

Pefloxacin-d5 is available in the following size(s): 1 mg, 5 mg, 10 mg.

How many pack sizes does Pefloxacin-d5 come in?

Pefloxacin-d5 is available in 3 different pack sizes.

Is Pefloxacin-d5 in stock?

Pefloxacin-d5 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Pefloxacin-d5?

Pefloxacin-d5 is manufactured by QuantiMol.

What is the estimated delivery time for Pefloxacin-d5?

Estimated delivery time for Pefloxacin-d5 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Pefloxacin-d5?

The safety data sheet for Pefloxacin-d5 is available here: http://file.medchemexpress.com/batch_PDF/HY-B0147S/Pefloxacin-d5-SDS-MedChemExpress.pdf.

Pefloxacin-d5

Pefloxacin-d5 (Pefloxacinium-d5) is the deuterium labeled Pefloxacin. Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC50 of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC90s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies[1][2][3][4][5][6][7][8][9].

Product Specifications

CAS Number

1228182-51-1

Product Name Alternative

Pefloxacinium-d5

UNSPSC

12352005

Hazard Statement

H302

Target

Antibiotic; Bacterial; DNA/RNA Synthesis; Isotope-Labeled Compounds; Parasite; Topoisomerase

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Others

Field of Research

Infection; Inflammation/Immunology

Purity

98.33

Solubility

10 mM in DMSO

Smiles

O=C(C1=CN(C([2H])([2H])C([2H])([2H])[2H])C2=C(C=C(F)C(N3CCN(C)CC3)=C2)C1=O)O

Molecular Formula

C17H15D5FN3O3

Molecular Weight

338.39

Precautions

P264-P270-P330-P501

References & Citations

[1]Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61 (3) :377-92.|[2]Hussy P, et al. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29 (6) :1073-8.|[3]Clarke AM, et al. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams. J Antimicrob Chemother. 1985 Jan;15 (1) :39-44.|[4]Jones BM, et al. Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections. J Antimicrob Chemother. 1986 Jun;17 (6) :739-46.|[5]Tabary X, et al. Effect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and clorobiocin on Escherichia coli topoisomerase I. Antimicrob Agents Chemother. 1987 Dec;31 (12) :1925-8.|[6]Fantin B, et al. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother. 1991 Jul;35 (7) :1413-22.|[7]Sun YW, et al. Pefloxacin and ciprofloxacin increase UVA-induced edema and immune suppression. Photodermatol Photoimmunol Photomed. 2001 Aug;17 (4) :172-7.|[8]Truffot-Pernot C, et al. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle. 1991 Mar;72 (1) :57-64.|[9]Salmon D, et al. Activities of pefloxacin and ciprofloxacin against experimental malaria in mice. Antimicrob Agents Chemother. 1990 Dec;34 (12) :2327-30.